Related Experiment Video
Updated: Apr 28, 2026
The In ovo CAM-assay as a Xenograft Model for Sarcoma
Published on: July 17, 2013
Immunohistochemical localization of steroid receptor coactivators in chondrosarcoma: an in vivo tissue microarray
Wei Li1, Jingshu Fu2, Chen Bian3
1National & Regional United Engineering Laboratory of Tissue Engineering, Department of Orthopaedics, Southwest Hospital, Third Military Medical University, Chongqing 400038, China; Department of Orthopedic Surgery, Affiliated Hospital of Bengbu Medical College, Bengbu 233030, Anhui Province, China.
Abstract:
Chondrosarcoma is the second most common type of primary bone malignancy following up osteosarcoma, characterized by resistance to conventional chemotherapeutic agents and radiation regimens. The p160 family members steroid receptor coactivator-1 and -3 (SRC-1 and SRC-3) have been implied in the regulation of cancer growth, migration, invasion, metastasis and chemotherapeutic resistance; but we still lack detailed information about the levels of SRCs in chondrosarcoma. In this study, expression of SRC-1 and SRC-3 in chondrosarcoma was examined by immunohistochemistry with tissue microarrays; the four score system (0, 1, 2 and 3) was used to evaluate the staining. The results showed that there were no gender-, site- or age-differences regarding the expression of SRC-1 or SRC-3 (p>0.05); organ (bone or cartilage) -differences were only detected for SRC-1 but not SRC-3 (p<0.05). Significant higher levels of SRC-1 and SRC-3 were detected in MDC and PDC when compared to WDC. Our study clearly demonstrated differentiation-dependant expression of SRC-1 and SRC-3 in chondrosarcoma, may be novel targets for the prognosis and/or treatment of chondrosarcoma, would have opened a new avenue and established foundation for studying chondrosarcoma.
Insights
Steroid receptor coactivators SRC-1 and SRC-3 show differentiation-dependent expression in chondrosarcoma, a bone cancer resistant to standard treatments. These findings suggest SRC-1 and SRC-3 may be potential therapeutic targets for chondrosarcoma.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Chondrosarcoma is a primary bone malignancy resistant to chemotherapy and radiation.
- Steroid receptor coactivators (SRCs), including SRC-1 and SRC-3, are implicated in various cancers but their role in chondrosarcoma is unclear.
Purpose of the Study:
- To investigate the expression levels of SRC-1 and SRC-3 in chondrosarcoma.
- To determine if SRC-1 and SRC-3 expression correlates with tumor differentiation or other clinical factors.
Main Methods:
- Immunohistochemistry was used to evaluate SRC-1 and SRC-3 expression in chondrosarcoma tissue microarrays.
- A four-score system (0-3) was applied for staining evaluation.
- Statistical analysis was performed to identify correlations with gender, site, age, organ, and differentiation.
Main Results:
- No significant differences in SRC-1 or SRC-3 expression were found based on gender, site, or age.
- Organ-specific differences were observed for SRC-1 but not SRC-3.
- Significantly higher levels of both SRC-1 and SRC-3 were detected in moderately and poorly differentiated chondrosarcoma compared to well-differentiated tumors.
Conclusions:
- SRC-1 and SRC-3 expression is dependent on chondrosarcoma differentiation.
- These findings highlight SRC-1 and SRC-3 as potential novel targets for chondrosarcoma prognosis and treatment.
More Related Videos
Related Concept Videos
01:22Immunocytochemistry and Immunohistochemistry
These...
01:27Tumor Immunotherapy
02:07Tumor Progression
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...